Pfizer considers raising bid for AstraZeneca

Pfizer Inc is planning to return with a higher bid for British rival AstraZeneca Plc before the US drugmaker considers going hostile, Bloomberg reported on Monday, citing people familiar with the matter.

The new offer will increase the value modestly above the current 50 pounds ($84.36) per share level while increasing the cash portion, two people familiar with the matter told Bloomberg.

Both Pfizer and AstraZeneca could not be reached for comment outside of business hours.

On May 2, AstraZeneca turned down a sweetened Pfizer cash and stock offer that valued the British company at 63 billion pounds ($106 billion).

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India must follow China on its path to the future

    There are many theories, real and imagined, doing the rounds in the national and international media about Barack Obama’s overtures to ‘rebalance

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Will the adventurous UGC succeed?

The impact of the Modi government on the education sector ...

Zehra Naqvi

The urge to tell stories

One wants to tell a story, like Scheherzade, in order ...

Dharmendra Khandal

Don’t interfere with nature

Just before we celebrated the news of tiger numbers swelling, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture